MassDevice Q&A

June 30, 2009 by MassDevice staff

Q&A Features

10/01/2014 by Brian Johnson

Orange County, Calif.'s most-connected man, OCTANe's Matthew Jenusaitis talks to MassDevice.com about OCTANe's 2014 Medical Device Investor Forum.

OCTANe's Matthew Jenusaitis

OCTANe, the industry council responsible for promoting the innovation climate in Orange County, Calif., existed before Matthew Jenusaitis arrived, but he has put his mark on the organization's impact on one of the world's largest med tech clusters.

Jenusaitis' medtech pedigree, which includes 15 years at Boston Scientific (NYSE:...

09/24/2014 by Brad Perriello

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells MassDevice.com.

What's behind the slump in early-stage medtech investment?

It's a hard world out there for those looking to turn their cutting edge medical device ideas into commercial products, with investors shying away from...

09/03/2014 by Brad Perriello

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

YYmeta

Last year, when Harvard Bioscience (NSDQ:HBIO) spun out its regenerative medicine business as...

08/15/2014 by Arezu Sarvestani

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

07/31/2014 by Brian Johnson

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

The CardioMEMS story didn't end when St. Jude Medical (NYSE:STJ) acquired the Georgia-based company in June, paying $375 million for the stake it didn’t already own, valuing the implantable heart failure monitor company at $463 million total.

But the deal did end an 11-year commitment by...

07/10/2014 by Brad Perriello

Calhoun Vision CEO Verne Sharma tells MassDevice.com why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

For years the Holy Grail of ophthalmology has been to give patients the ability to see clearly both and near and far distances. Verne Sharma, CEO of Calhoun Vision, thnks his company's light-adjustable lens has reached that goal.

The LAL device uses a unique blend of light-sensitive polymers to...

Syndicate content
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp